Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Clin Cardiol. 2024 Jan;47(1):e24173. doi: 10.1002/clc.24173. Epub 2023 Oct 11.
Pulmonary arterial hypertension (PAH) is a widespread condition that affects around 1% of the global population, with a higher prevalence among older individuals. The approach to managing PAH has undergone significant changes, requiring extensive treatment strategies. Sotatercept, an FDA-approved medication, has recently attracted attention for its potential role in PAH therapy. However, information on its safety and effectiveness is scarce. In this study, we performed a meta-analysis of existing randomized clinical trials to assess the impact of Sotatercept on PAH patients. Our findings revealed that those treated with Sotatercept showed greater improvement in pulmonary vascular resistance and World Health Organization functional class compared with placebo recipients. The occurrence of adverse events was similar between both groups. Importantly, the Sotatercept group displayed a considerably higher number of cases with an increase in hemoglobin levels. Considering that about 33% of PAH patients experience anemia and both anemia and polycythemia can adversely affect disease prognosis, additional research is necessary to establish the potential advantages and disadvantages of Sotatercept as a treatment choice, specifically regarding its erythropoietic properties.
肺动脉高压（PAH）是一种广泛存在的病症，影响着全球约 1%的人口，在老年人中更为常见。PAH 的治疗方法已经发生了重大变化，需要广泛的治疗策略。Sotatercept 是一种获得 FDA 批准的药物，最近因其在 PAH 治疗中的潜在作用而受到关注。然而，关于其安全性和有效性的信息还很有限。在这项研究中，我们对现有的随机临床试验进行了荟萃分析，以评估 Sotatercept 对 PAH 患者的影响。我们的研究结果表明，与安慰剂组相比，接受 Sotatercept 治疗的患者的肺血管阻力和世界卫生组织功能分级有更大的改善。两组不良反应的发生情况相似。重要的是，Sotatercept 组有更高比例的血红蛋白水平升高的病例。考虑到约 33%的 PAH 患者患有贫血，并且贫血和红细胞增多症都可能对疾病预后产生不利影响，因此需要进一步的研究来确定 Sotatercept 作为治疗选择的潜在优势和劣势，特别是关于其促红细胞生成特性。
